| Document |
Document Title |
|
WO/1996/021464A1 |
The present invention relates to the delivery of antigens. Delivery systems are provided that include the antigen and acylated or sulfonated amino acids or poly amino acids. Methods of preparation and administration of these compositions...
|
|
WO/1996/021642A1 |
The process comprises a first step of esterification of an aminoacid and is characterized by a second step of condensation of a fatty acid chloride with an esterified amino acid derivative. It relates to the synthesis of surfactant compo...
|
|
WO/1996/020932A1 |
The present invention concerns compounds that possess anti-infective activity. The invention encompasses methods of use of such compounds for treatment or prevention of infectious diseases, such as parasitic and viral diseases, including...
|
|
WO/1996/020920A1 |
An amidinonaphthyl ester derivative efficacious in treating thrombosis.
|
|
WO/1996/020917A1 |
A novel substituted amidinonaphthyl ester derivative which is efficacious against thrombosis and represented by the general formula (I) or an acid-addition salt thereof usable as a medicine, wherein R1 and R2 are each as defined in the s...
|
|
WO/1996/018607A1 |
A compound represented by general formula (1) or possible stereoisomers and optical isomers thereof, and medicinally acceptable salts of these compounds, wherein R1 represents SR6 or NHR7; R6 represents C1-C6 alkyl, etc.; R7 represents h...
|
|
WO/1996/018642A1 |
Compounds termed "betides" mimic peptides and contain one or more residues of aminoglycine, C'alpha'-aminoalanine, aminosarcosine or the like wherein the side chain amino group has been acylated and optionally also alkylated. Generally, ...
|
|
WO/1996/018372A2 |
Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or ac...
|
|
WO/1996/018608A1 |
A compound represented by general formula (1),zor possible stereoisomers and optical isomers thereof, and medicinally acceptable salts of these, (wherein R1 represents SR6 or NR7R8; R6 represents C1-C6 alkyl, etc.; R7 represents hydrogen...
|
|
WO/1996/018644A1 |
The present invention discloses peptide aldehydes of formula (I) which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them a...
|
|
WO/1996/017822A1 |
Novel complex salts of phosphoric and amino acids which are mainly composed of a basic amino acid, an alkaline earth metal and a phosphoric acid selected from among orthophosphoric, condensed phosphoric and metaphosphoric acids and which...
|
|
WO/1996/016027A1 |
Compounds of formula (I) and their pharmaceutically acceptable salts inhibit matrix metalloproteases, such as stromelysin, gelatinase, matrilysin and collagenase, and are useful in the treatment of mammals having disease-states alleviate...
|
|
WO/1996/014857A1 |
Disclosed herein are inhibitors of the multicatalytic protease enzyme which are represented by general formula (I). Constituent members and preferred constituent members are disclosed herein. Methodologies for making and using the disclo...
|
|
WO/1996/014294A1 |
A toner resin composition comprising a toner resin and an aromatic sulphonic acid salt of a guanidine such as the bis-diphenylguanidine salt of naphthalene-1,5-disulphonic acid. The diphenyl guanidine salts are novel.
|
|
WO/1996/012474A1 |
The present invention relates to compositions and methods for orally delivering antigens. The antigen and an adjuvant are combined with an acylated amino acid or polyamino acid and, a sulfonated amino acid or polyamino acid, or a salt of...
|
|
WO/1996/012473A1 |
Modified amino acid compounds useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.
|
|
WO/1996/012475A1 |
Methods for transporting a biologically active agent across a cellular membrane or a lipid bilayer. A first method includes the steps of: a) providing a biologically active agent which can exist in a native conformational state, a denatu...
|
|
WO/1996/009297A1 |
Novel compounds, compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders are described. The compounds, compositions and methods are effective for the prevention and treatment of in...
|
|
WO/1996/008469A1 |
The present invention is the novel synthesis of sterically hindered penta-substituted guanidines by a process in which (1a) an isocyanate is reacted first with a di-substituted amine or (1b) a urea is reacted with two moles of a mono-sub...
|
|
WO/1996/006825A1 |
A compound represented by general formula (I-2) or a pharmaceutically acceptable acid-addition salt thereof, useful as an anti-microbial against Helicobacter pylori and as a medicinal composition for treating Helicobacter pylori infectio...
|
|
WO/1996/004240A1 |
Hydrosoluble organic salts of creatine are disclosed. The salts are useful in the dietetic and food industry.
|
|
WO/1996/004241A2 |
Guanidine derivatives of formula (I) wherein R1 is hydrogen, hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, acyl(lower)alkoxy, acyl(lower)alkenyl, or acyl, and R2 is ar(lower)alkenyl; aryl substituted with two suitable substituents;...
|
|
WO/1996/001840A1 |
The present invention is directed to new cationic lipids and intermediates in their synthesis that are useful for transfecting nucleic acids or peptides into prokaryotic or eukaryotic cells. The lipids comprise one or two arginine, lysin...
|
|
WO/1996/001841A1 |
The present invention is directed to new cationic lipids and intermediates in their synthesis that are useful for transfecting nucleic acids or peptides into prokaryotic or eukaryotic cells. The lipids comprise one or two substituted arg...
|
|
WO/1996/000716A1 |
A salt of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid with an organic basic cation of formula (I); Wherein R1 and R2 independently are lower alkyl, or if R1 is hydrogen H-N(R1)(R2) has the meaning of arginine or lysine or if R1...
|
|
WO/1995/035309A1 |
Compounds having the formula (I) are disclosed, in which the substituents have the meanings given in the description, as well as their salts with physiologically acceptable acids and their stereoisomers, and intermediate products for pro...
|
|
WO/1995/032710A1 |
Compounds of the following general structure: X-Y-Z-Aryl-A-B, for example (I), which inhibit osteoclast-mediated bone resorption.
|
|
WO/1995/032945A1 |
The present invention describes compounds, methods and compositions effective to treat mast-cell mediated inflammatory conditions, such as conjunctivitis, asthma and allergic rhinitis. The compounds of the invention comprise novel mono- ...
|
|
WO/1995/029926A1 |
Novel guanidino-substituted compounds are described having general formula (I) or a salt, hydrate or solvate thereof, in which X is selected from C, O, N and S; R1 and R3 are independently -(W)a-(R6)b-Z, wherein a and b are independently...
|
|
WO/1995/028838A1 |
The present invention relates to an oral delivery system, and in particular to modified amino acids or peptides for use as a delivery system of sensitive agents such as bioactive peptides. The modified amino acids or peptides can form no...
|
|
WO/1995/028377A1 |
Guanidine compounds of formula (I) or a pharmaceutically-acceptable salt, ester, amide or prodrug thereof, which are regulators of nitric oxyde synthase and are useful in the treatment of disorders of the vascular system including hypote...
|
|
WO/1995/026337A1 |
The present invention relates to compounds as represented by formula (I) that can maintain, increase, or restore sensitivity of cells to therapeutic or prophylatic agents. This comprising these compounds. The compounds and pharmaceutical...
|
|
WO/1995/024898A1 |
Novel complexes of nitric oxide (NO) and amines are described where the amine is a known cardiovascular agent having at least one or more primary or secondary amino groups and whereby the resulting complex is capable under physiological ...
|
|
WO/1995/024382A1 |
There is disclosed a novel amino glycol derivatives of L-N6-(1-iminoethyl)lysine, pharmaceutical compositions containing these novel compounds, and to their use in therapy, in particular their use as nitric oxide synthase inhibitors.
|
|
WO/1995/023132A1 |
This invention relates to methods of treatment of diseases and various other undesirable bodily states which involve the excessive, inappropriate, and/or prolonged activity of voltage-activated ion channels, and are ameliorated by admini...
|
|
WO/1995/022398A1 |
A process for recovering guanidine salts from diluted and contaminated aqueous solutions is described, wherein the corresponding aqueous solution (diluate) is subjected to electrodialysis and the guanidine salt is concentrated on the con...
|
|
WO/1995/021612A2 |
Method for indentifying a compound useful for the therapeutic treatment of a neurological disease or disorder such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, ...
|
|
WO/1995/020950A1 |
The present invention provides therapeutically useful substituted guanidines, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such guanidines.
|
|
WO/1995/016661A1 |
4,7,10,13,16,19-cis-Docosahexaenoic acid (DHA) salts with basic amino acids, in particular ariginine and lysine, have favourable therapeutical and technological characteristics (water solubility) compared with the starting acid.
|
|
WO/1995/014461A1 |
The present invention provides therapeutically useful substituted guanidines and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such guanidines.
|
|
WO/1995/014380A1 |
Amphiphiles containing an imidazolinium ring system are provided that are non-toxic to the host mammal. The amphiphiles are used to produce liposomes useful as carriers for delivering macromolecules intracellularly.
|
|
WO/1995/014381A1 |
Guanidine-based amphiphiles are provided that are non-toxic to the host mammal, especially a human host. The amphiphiles are used to produce liposomes useful as carriers for delivering macromolecules intracellularly.
|
|
WO/1995/014467A1 |
The present invention provides N,N'-diaryl substituted guanidines having therapeutic utility. The compounds of the present invention are represented by formula (I), wherein R and R1 represent hydrogen or other group and Ar and Ar1 repres...
|
|
WO/1995/014027A1 |
Novel guanidino-substituted compounds are described having general formula (I) or a salt, hydrate or solvate thereof, wherein X is selected from C, O, N and S; R1 is -(W)a-(R4)b-Z, wherein a and b are independently 0 or 1; W is NH, O or ...
|
|
WO/1995/012603A1 |
This invention is directed to compounds of formula (I): wherein R1 is mercapto, acetylthio, carboxy, hydroxycarbamoyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, benzyloxycarbamoyl or (i) (where R6 is optionally substituted aryl,...
|
|
WO/1995/012584A1 |
The novel compounds of formula (I), which is explained in the description, can be conventionally produced and used as medical substances.
|
|
WO/1995/012021A1 |
Antimicrobial treatment of textile material with an oligomeric or polymeric biguanide and a strong organic acid having a pK value below 4.5. Acid protects treated material against yellowing in the presence of chlorine bleaches and loss o...
|
|
WO/1995/009838A1 |
This invention relates to compounds and pharmaceutical compositions, and methods for inhibiting or preventing the amyloid protein deposits in the brain which are associated with Alzheimer's disease and aged Down's syndrome patients. More...
|
|
WO/1995/007291A1 |
Kininogenase inhibiting peptides or peptide analogues with C-terminal residues related to agmatine or noragmatine.
|
|
WO/1995/005366A1 |
The present invention is concerned with compounds having formula (I), the pharmaceutically acceptable acid addition salts thereof, and the stereochemically isomeric forms thereof, wherein R1 is hydrogen or C1-6alkyl; R2 is hydrogen or C1...
|
